KCNJ5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1239446	0.72	20/20
SCHEMBL1237053	0.56	20/20
SCHEMBL1238635	0.56	20/20
SCHEMBL1240105	0.56	20/20
SCHEMBL1239310	0.54	20/20
SCHEMBL1239394	0.51	20/20
SCHEMBL1239786	0.51	20/20
SCHEMBL1237257	0.51	20/20
SCHEMBL1238555	0.51	20/20
SCHEMBL1238341	0.59	19/20
SCHEMBL1239289	0.66	18/20
SCHEMBL1238084	0.66	18/20
SCHEMBL1239098	0.63	18/20
SCHEMBL1238133	0.61	18/20
SCHEMBL1239151	0.60	18/20
Hydrochloric Acid (SCHEMBL1238595)	0.51	18/20
Hydrochloric Acid (SCHEMBL1236611)	0.49	18/20
SCHEMBL1238206	0.82	17/20
SCHEMBL1236810	0.81	17/20
Hydrochloric Acid (SCHEMBL1238136)	0.77	17/20

Clinical trials — most relevant to KCNJ5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)	PHASE4	UNKNOWN
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery	PHASE4	RECRUITING
Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)	PHASE2/PHASE3	RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Mutation-specific Therapy for the Long QT Syndrome	PHASE2	COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients	PHASE2	COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss	PHASE2	COMPLETED
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo	PHASE2	COMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients.	nan	UNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)	nan	UNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism	nan	COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome	nan	RECRUITING
Qatar Cardiovascular Biorepository of AF Patients	nan	UNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Characteristics of Andersen-Tawil Syndrome	nan	COMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats	nan	COMPLETED
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants	nan	RECRUITING
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia	nan	UNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Role of KATP Channel Loss in Type 2 Diabetes	nan	RECRUITING
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNJ5 binder may also engage these)

Protein	Name	Similarity
F1MYR9	—	1.000	F1MYR9 →
O02670	—	1.000	O02670 →
P48545	—	1.000	P48545 →
P48548	—	1.000	P48548 →
P48542	—	0.992	P48542 →
P49658	—	0.992	P49658 →
P48550	—	0.989	P48550 →
P52190	—	0.987	P52190 →
KCNJ6	G protein-activated inward rectifier potassium channel 2	0.986	landscape →
Q5NVJ6	—	0.985	Q5NVJ6 →
P52189	—	0.985	P52189 →
KCNJ3	G protein-activated inward rectifier potassium channel 1	0.985	landscape →
KCNJ4	Inward rectifier potassium channel 4	0.984	landscape →
Q91ZF1	—	0.984	Q91ZF1 →
Q92806	—	0.984	Q92806 →
Q64198	—	0.984	Q64198 →
O88932	—	0.984	O88932 →
Q4TZY1	—	0.983	Q4TZY1 →
Q99712	—	0.982	Q99712 →
Q63511	—	0.982	Q63511 →
Q9JM63	—	0.982	Q9JM63 →
Q90854	—	0.981	Q90854 →
Q14500	—	0.980	Q14500 →
B7U540	—	0.980	B7U540 →
O70339	—	0.980	O70339 →
P52188	—	0.979	P52188 →
P52187	—	0.979	P52187 →
P48543	—	0.979	P48543 →
P63251	—	0.979	P63251 →
P78508	—	0.979	P78508 →